Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

A commonly carried genetic variant in the delta opioid receptor gene, OPRD1, is associated with smaller regional brain volumes: replication in elderly and young populations.

Roussotte FF, Jahanshad N, Hibar DP, Sowell ER, Kohannim O, Barysheva M, Hansell NK, McMahon KL, de Zubicaray GI, Montgomery GW, Martin NG, Wright MJ, Toga AW, Jack CR Jr, Weiner MW, Thompson PM; ADNI.

Hum Brain Mapp. 2014 Apr;35(4):1226-36. doi: 10.1002/hbm.22247. Epub 2013 Feb 21.

2.

Altered regional brain volumes in elderly carriers of a risk variant for drug abuse in the dopamine D2 receptor gene (DRD2).

Roussotte FF, Jahanshad N, Hibar DP, Thompson PM; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Brain Imaging Behav. 2015 Jun;9(2):213-22. doi: 10.1007/s11682-014-9298-8.

3.

Effect of EPHA1 genetic variation on cerebrospinal fluid and neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts.

Wang HF, Tan L, Hao XK, Jiang T, Tan MS, Liu Y, Zhang DQ, Yu JT; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;44(1):115-23. doi: 10.3233/JAD-141488.

PMID:
25182741
4.

Hippocampal Sclerosis of Aging, a Common Alzheimer's Disease 'Mimic': Risk Genotypes are Associated with Brain Atrophy Outside the Temporal Lobe.

Nho K, Saykin AJ; Alzheimer’s Disease Neuroimaging Initiative, Nelson PT.

J Alzheimers Dis. 2016;52(1):373-83. doi: 10.3233/JAD-160077.

5.

Case-control association analysis of polymorphisms in the δ-opioid receptor, OPRD1, with cocaine and opioid addicted populations.

Crist RC, Ambrose-Lanci LM, Vaswani M, Clarke TK, Zeng A, Yuan C, Ferraro TN, Hakonarson H, Kampman KM, Dackis CA, Pettinati HM, O'Brien CP, Oslin DW, Doyle GA, Lohoff FW, Berrettini WH.

Drug Alcohol Depend. 2013 Jan 1;127(1-3):122-8. doi: 10.1016/j.drugalcdep.2012.06.023. Epub 2012 Jul 12.

6.

Association analysis of delta-opioid receptor gene polymorphisms in methamphetamine dependence/psychosis.

Kobayashi H, Hata H, Ujike H, Harano M, Inada T, Komiyama T, Yamada M, Sekine Y, Iwata N, Iyo M, Ozaki N, Itokawa M, Naka M, Ide S, Ikeda K, Numachi Y, Sora I.

Am J Med Genet B Neuropsychiatr Genet. 2006 Jul 5;141B(5):482-6.

PMID:
16741914
7.

Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.

Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P, Goldberg TE; Alzheimer's Disease Neuroimaging Initiative.

Arch Gen Psychiatry. 2011 Sep;68(9):961-9. doi: 10.1001/archgenpsychiatry.2011.96.

PMID:
21893661
9.

Relationship of the delta-opioid receptor gene to heroin abuse in a large Chinese case/control sample.

Xu K, Liu XH, Nagarajan S, Gu XY, Goldman D.

Am J Med Genet. 2002 Jun 1;110(1):45-50.

PMID:
12116270
10.

OPRD1 Genetic Variation and Human Disease.

Crist RC, Clarke TK.

Handb Exp Pharmacol. 2018;247:131-145. doi: 10.1007/164_2016_112. Review.

PMID:
28035534
11.

Defining multivariate normative rules for healthy aging using neuroimaging and machine learning: an application to Alzheimer's disease.

Andrade de Oliveira A, Carthery-Goulart MT, Oliveira Júnior PP, Carrettiero DC, Sato JR.

J Alzheimers Dis. 2015;43(1):201-12. doi: 10.3233/JAD-140189.

PMID:
25079801
12.

Association of polymorphisms in pharmacogenetic candidate genes (OPRD1, GAL, ABCB1, OPRM1) with opioid dependence in European population: a case-control study.

Beer B, Erb R, Pavlic M, Ulmer H, Giacomuzzi S, Riemer Y, Oberacher H.

PLoS One. 2013 Sep 25;8(9):e75359. doi: 10.1371/journal.pone.0075359. eCollection 2013.

13.

CSF and brain structural imaging markers of the Alzheimer's pathological cascade.

Yang X, Tan MZ, Qiu A.

PLoS One. 2012;7(12):e47406. doi: 10.1371/journal.pone.0047406. Epub 2012 Dec 19.

14.

Graphical neuroimaging informatics: application to Alzheimer's disease.

Van Horn JD, Bowman I, Joshi SH, Greer V.

Brain Imaging Behav. 2014 Jun;8(2):300-10. doi: 10.1007/s11682-013-9273-9.

15.

Association of OPRD1 Gene Variants with Opioid Dependence in Addicted Male Individuals Undergoing Methadone Treatment in the North of Iran.

Sharafshah A, Fazel H, Albonaim A, Omarmeli V, Rezaei S, Mirzajani E, Ajamian F, Keshavarz P.

J Psychoactive Drugs. 2017 Jul-Aug;49(3):242-251. doi: 10.1080/02791072.2017.1290303. Epub 2017 Mar 1.

PMID:
28632076
16.

An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans.

Crist RC, Clarke TK, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ, Ling W, Hillhouse MP, Bruce RD, Woody G, Berrettini WH.

Neuropsychopharmacology. 2013 Sep;38(10):2003-10. doi: 10.1038/npp.2013.99. Epub 2013 Apr 23. Erratum in: Neuropsychopharmacology. 2014 Mar;39(4):1039.

17.

Relationship between CSF biomarkers of Alzheimer's disease and rates of regional cortical thinning in ADNI data.

Tosun D, Schuff N, Shaw LM, Trojanowski JQ, Weiner MW; Alzheimer's Disease NeuroImaging Initiative.

J Alzheimers Dis. 2011;26 Suppl 3:77-90. doi: 10.3233/JAD-2011-0006.

18.

Clinical and multimodal biomarker correlates of ADNI neuropathological findings.

Toledo JB, Cairns NJ, Da X, Chen K, Carter D, Fleisher A, Householder E, Ayutyanont N, Roontiva A, Bauer RJ, Eisen P, Shaw LM, Davatzikos C, Weiner MW, Reiman EM, Morris JC, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Acta Neuropathol Commun. 2013 Oct 9;1:65. doi: 10.1186/2051-5960-1-65.

19.

The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.

Li X, Li TQ, Andreasen N, Wiberg MK, Westman E, Wahlund LO.

J Intern Med. 2014 Apr;275(4):418-27. doi: 10.1111/joim.12164. Epub 2013 Dec 11.

20.

Supplemental Content

Support Center